Establishment of a nomogram for survival rate after liver resection for primary small hepatocellular carcinoma based on SEER data and external validation

Abstract

Objective To establish a nomogram for overall survival rate after liver resection for primary small hepatocellular carcinoma based on SEER data and external validation of Chinese data. Methods The data of 1809 patients, registered in National Cancer Institute SEER database in 2004-2015, who underwent hepatectomy for primary small hepatocellular carcinoma were extracted as modeling group, and 158 patients with small hepatocellular carcinoma who underwent hepatectomy in Affiliated Hospital of North Sichuan Medical College from 2010 to 2017 were collected as validation group. The univariate Cox risk regression analysis, lasso regression analysis, and multivariate Cox hazard regression analysis were used to investigate the influencing factors for OS after hepatectomy in patients with small hepatocellular carcinoma. A nomogram was established based on the independent influencing factors for OS, and index of concordance (C-index), calibration curves, and receiver operating characteristic (ROC) curve were used to analyze the predictive ability of the nomogram. The Kaplan-Meier survival analysis and the log-rank test were used to investigate the difference in survival between the high- and low-risk groups. Results The multivariate Cox hazard regression analysis showed that sex (hazard ratio [HR]=1.22, 95% confidence interval [CI]: 1.05-1.41, P=0.010), Seer stage (HR=1.51, 95%CI: 1.23-1.85, P < 0.001; HR=10.31, 95%CI: 2.53-42.04, P=0.001), tumor diameter (HR=1.22, 95%CI: 1.06-1.39, P=0.004), vascular invasion or metastasis (HR=1.43, 95%CI: 1.24-1.65, P < 0.001), and alpha-fetoprotein (HR=1.33, 95%CI: 1.16-1.54, P < 0.001) were independent risk factors for OS after hepatectomy for small hepatocellular carcinoma. The modeling group had a C-index of 0.621, and its area under the ROC curve at 1, 2, and 3 years was 0.666(95%CI 0.628-0.704), 0.678(95%CI 0.647-0.708), and 0.663(95%CI: 0.635-0.690), respectively; the validation group had a C-index of 0.718, and its area under the ROC curve at 1, 2, and 3 years was 0.695(95%CI: 0.593-0.797), 0.781(95%CI: 0.706-0.856), and 0.759(95%CI 0.669-0.848), respectively. Risk stratification was performed based on the nomogram, and the Kaplan-Meier survival analysis showed that for both the modeling group and the validation group, the low-risk group had a significantly better prognosis than the high-risk group (P < 0.01). Conclusion The model established for survival rate after liver resection for primary small hepatocellular carcinoma can predict the 1-, 2-, and 3-year OS rates and can thus be used in clinical practice in China.
- Carcinoma, Hepatocellular,
- Hepatectomy,
- Nomograms

FullText(HTML)

References(27)

References

[1]	TORRE LA, BRAY F, SIEGEL RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262.
[2]	WEN T, JIN C, FACCIORUSSO A, et al. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: An international expert consensus[J]. Hepatobiliary Surg Nutr, 2018, 7(5): 353-371. DOI: 10.21037/hbsn.2018.08.01.
[3]	AHN KS, KANG KJ. Appropriate treatment modality for solitary small hepatocellular carcinoma: Radiofrequency ablation vs. resection vs. transplantation?[J]. Clin Mol Hepatol, 2019, 25(4): 354-359. DOI: 10.3350/cmh.2018.0096.
[4]	LI CH, HU P, OU YJ, et al. Development and validation of nomogram for predicting survival outcomes in patients with small hepatocellular carcinoma[J]. J Third Mil Med Univ, 2020, 42(20): 2046-2056. DOI: 10.16016/j.1000-5404.202007005. 李传红, 胡鹏, 欧晏娇, 等. 预测小肝癌患者生存率列线图的建立和验证[J]. 第三军医大学学报, 2020, 42(20): 2046-2056. DOI: 10.16016/j.1000-5404.202007005.
[5]	ZHANG W, WANG X, JIANG R, et al. Effect of tumor size on cancer-specific survival in small hepatocellular carcinoma[J]. Mayo Clin Proc, 2015, 90(9): 1187-1195. DOI: 10.1016/j.mayocp.2015.06.018.
[6]	WEI Y, DAI F, YI Y, et al. Impact of local tumor lesion treatments and preoperative indicators on the survival of patients with small hepatocellular carcinomas[J]. Oncol Lett, 2018, 16(4): 5050-5058. DOI: 10.3892/ol.2018.9263.
[7]	VOLK ML. Unfair priority for HCC: A problem whose ideal solution remains unsolved[J]. Am J Transplant, 2010, 10(7): 1507-1508. DOI: 10.1111/j.1600-6143.2010.03154.x.
[8]	ZANG YY, LONG PY, HAN ZW, et al. Establishment and verification of a nomogram for predicting patient prognosis after hepatectomy for hepatocellular carcinoma[J]. J Clin Hepatol, 2019, 35(10): 2225-2230. DOI: 10.3969/j.issn.1001-5256.2019.10.019. 臧游亚, 龙沛雲, 韩志伟, 等. 肝细胞癌患者肝切除术后预后列线图的建立与验证[J]. 临床肝胆病杂志, 2019, 35(10): 2225-2230. DOI: 10.3969/j.issn.1001-5256.2019.10.019.
[9]	SALVATORE M, JEON J, MEZA R. Changing trends in liver cancer incidence by race/ethnicity and sex in the US: 1992-2016[J]. Cancer Causes Control, 2019, 30(12): 1377-1388. DOI: 10.1007/s10552-019-01237-4.
[10]	BALACHANDRAN VP, GONEN M, SMITH JJ, et al. Nomograms in oncology: More than meets the eye[J]. Lancet Oncol, 2015, 16(4): e173-e180. DOI: 10.1016/S1470-2045(14)71116-7.
[11]	JADLOWIEC CC, TANER T. Liver transplantation: Current status and challenges[J]. World J Gastroenterol, 2016, 22(18): 4438-4445. DOI: 10.3748/wjg.v22.i18.4438.
[12]	SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[13]	AN L, ZENG HM, ZHENG RS, et al. Liver cancer epidemiology in China, 2015[J]. Chin J Oncol, 2019, 41(10): 721-722. DOI: 10.3760/cma.j.issn.0253-3766.2019.10.001. 安澜, 曾红梅, 郑荣寿, 等. 2015年中国肝癌流行情况分析[J]. 中华肿瘤杂志, 2019, 41(10): 721-722. DOI: 10.3760/cma.j.issn.0253-3766.2019.10.001.
[14]	CHEN K, HUO RR, CHEN SY, et al. Analysis of the relationship between gender and prognosis of patients after liver resection for hepatocellular carcinoma[J]. Chin J Hepatobiliary Surg, 2020, 26(5): 330-334. DOI: 10.3760/cma.j.cn113884-20190909-00290. 陈康, 霍荣瑞, 陈肃伊, 等. 性别对肝细胞癌患者肝切除术后预后的影响[J]. 中华肝胆外科杂志, 2020, 26(5): 330-334. DOI: 10.3760/cma.j.cn113884-20190909-00290.
[15]	GALLE PR, FOERSTER F, KUDO M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma[J]. Liver Int, 2019, 39(12): 2214-2229. DOI: 10.1111/liv.14223.
[16]	ZHU Y, XIA QQ, LUO J, et al. Application of combined detection of alpha-fetoprotein, alpha-fetoprotein heterogeneity and TNF-α factor in the diagnosis of primary liver cancer and its clinical value[J]. J Clin Exp Med, 2020, 19(4): 383-386. DOI: 10.3969/j.issn.1671-4695.2020.04.014. 朱艳, 夏芹芹, 罗俊, 等. 甲胎蛋白、甲胎蛋白异质体与TNF-α因子联合检测在原发性肝癌诊断中的应用价值[J]. 临床和实验医学杂志, 2020, 19(4): 383-386. DOI: 10.3969/j.issn.1671-4695.2020.04.014.
[17]	GRAHAM JA, MELANCON JK, SHETTY K, et al. Liver transplantation should be offered to patients with small solitary hepatocellular carcinoma and a positive serum alpha fetoprotein rather than resection[J]. Am J Surg, 2013, 205(4): 374-380. DOI: 10.1016/j.amjsurg.2012.12.002.
[18]	TANG H, TANG XY, LIU M, et al. Targeting alpha-fetoprotein represses the proliferation of hepatoma cells via regulation of the cell cycle[J]. Clin Chim Acta, 2008, 394(1-2): 81-88. DOI: 10.1016/j.cca.2008.04.012.
[19]	LU Y, ZHU M, LI W, et al. Alpha fetoprotein plays a critical role in promoting metastasis of hepatocellular carcinoma cells[J]. J Cell Mol Med, 2016, 20(3): 549-558. DOI: 10.1111/jcmm.12745.
[20]	ZHANG XP, CHEN ZH, ZHOU TF, et al. A nomogram to predict early postoperative recurrence of hepatocellular carcinoma with portal vein tumour thrombus after R0 liver resection: A large-scale, multicenter study[J]. Eur J Surg Oncol, 2019, 45(9): 1644-1651. DOI: 10.1016/j.ejso.2019.03.043.
[21]	WANG Y, SUN K, SHEN J, et al. Novel prognostic nomograms based on inflammation-related markers for patients with hepatocellular carcinoma underwent hepatectomy[J]. Cancer Res Treat, 2019, 51(4): 1464-1478. DOI: 10.4143/crt.2018.657.
[22]	YUAN SX, ZHOU WP. Progress and hot spots of comprehensive treatment for primary liver cancer[J]. Chin J Dig Surg, 2021, 20(2) : 163-170. DOI: 10.3760/cma.j.cn115610-20201211-00776. 袁声贤, 周伟平. 原发性肝癌综合治疗的进展和热点[J]. 中华消化外科杂志, 2021, 20(2): 163-170. DOI: 10.3760/cma.j.cn115610-20201211-00776.
[23]	LU XY, XI T, LAU WY, et al. Pathobiological features of small hepatocellular carcinoma: Correlation between tumor size and biological behavior[J]. J Cancer Res Clin Oncol, 2011, 137(4): 567-575. DOI: 10.1007/s00432-010-0909-5.
[24]	MINAGAWA M, IKAI I, MATSUYAMA Y, et al. Staging of hepatocellular carcinoma: Assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13, 772 patients in Japan[J]. Ann Surg, 2007, 245(6): 909-922. DOI: 10.1097/01.sla.0000254368.65878.da.
[25]	ZHOU DD, LIU XL, JIANG TT, et al. Analysis and comparison of common prognostic prediction models for liver cancer[J]. Chin J Clin Oncol, 2020, 47(24): 1281-1286. DOI: 10.3969/j.issn.1000-8179.2020.24.149. 周冬冬, 刘晓利, 姜婷婷, 等. 常见肝癌预后预测模型的分析与比较[J]. 中国肿瘤临床, 2020, 47(24): 1281-1286. DOI: 10.3969/j.issn.1000-8179.2020.24.149.
[26]	WEN L, WENG S, YAN C, et al. A radiomics nomogram for preoperative prediction of early recurrence of small hepatocellular carcinoma after surgical resection or radiofrequency ablation[J]. Front Oncol, 2021, 11: 657039. DOI: 10.3389/fonc.2021.657039.
[27]	ZHOU ZW, LIU YC, XIANG BD, et al. Global outlook for primary liver cancer: Prevalence, risk, factors and population attribution scores[J]. Chin J Oncol Prev Treat, 2021, 13(1): 14-21. DOI: 10.3969/j.issn.1674-5671.2021.01.03. 周泽文, 刘颖春, 向邦德, 等. 原发性肝癌的全球展望: 流行情况、危险因素和人群归因分值[J]. 中国癌症防治杂志, 2021, 13(1): 14-21. DOI: 10.3969/j.issn.1674-5671.2021.01.03.

Relative Articles

[1]	Yiming ZHAO, Kaiyang LI, Mei YANG, Qi ZHAO. The role of CD8⁺ T cells in nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2024, 40(10): 2087-2091. doi: 10.12449/JCH241026
[2]	Lixian WU, Weiqiang ZHENG, Huanqin HAN. Effect of different antiviral drugs in reducing the risk of hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 1165-1168. doi: 10.3969/j.issn.1001-5256.2022.05.040
[3]	Mingyang FENG, Hui WANG. Selection of antiviral drugs for patients with hepatitis B virus-associated hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2452-2456. doi: 10.3969/j.issn.1001-5256.2022.11.004
[4]	Hui HUANG, Lieming XU, Jian PING, Yang ZHOU. Value of Fuzheng Huayu prescription in preventing liver fibrosis by altering the phenotypic function of CD8⁺ T lymphocytes in the liver of mice with acute liver injury[J]. Journal of Clinical Hepatology, 2022, 38(2): 342-346. doi: 10.3969/j.issn.1001-5256.2022.02.017
[5]	Haipeng WANG, Yi LIU, Donghui LI, Guanghui SHEN. Expression of interleukin-33 in hepatocellular carcinoma patients and its role in regulating CD8⁺ T cell function[J]. Journal of Clinical Hepatology, 2022, 38(1): 117-123. doi: 10.3969/j.issn.1001-5256.2022.01.018
[6]	Xiaofei YANG, Linxu WANG, Changxing HUANG, Jie DONG, Haifeng HU, Zhanhu BI, Jianqi LIAN, Ye ZHANG. Mechanism of gamma-chain cytokines in regulating the expression of T-cell immunoglobulin and mucin domain-containing molecule 3 in CD8⁺ T cells of chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2021, 37(5): 1059-1064. doi: 10.3969/j.issn.1001-5256.2021.05.017
[7]	Qian ZHU, Mingyuan ZHANG, Junqi NIU. Advances in direct-acting antiviral therapy for liver transplant recipients with HCV-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(10): 2444-2447. doi: 10.3969/j.issn.1001-5256.2021.10.039
[8]	Song XUE, Gaobo HUANG, Xiaofei YANG, Ye ZHANG, Yu LI. Influence of interleukin-6 on the expression and function of programmed death-1 in CD8⁺ T cells from patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(10): 2332-2337. doi: 10.3969/j.issn.1001-5256.2021.10.015
[9]	CHEN HongYu, XU XiaoYuan. Drug resistance of direct-acting antivirals in genotype 2/3 hepatitis C virus[J]. Journal of Clinical Hepatology, 2020, 36(11): 2553-2556. doi: 10.3969/j.issn.1001-5256.2020.11.035
[10]	LIU YuWei, JIN JingLan, REN TianYi, GAO XiuZhu, LI Jie, ZHU Qing, NIU JunQi. Effect of direct-acting antiviral on the recurrence hepatitis C virus-related hepatocellular carcinoma after curative treatment: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(12): 2714-2719. doi: 10.3969/j.issn.1001-5256.2020.12.015
[11]	Xiong Fang, Ma YanPin, Bao XuLi, Lu: Jun. Change in the level of T-cell receptor rearrangement excision circles after antiviral therapy in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2019, 35(11): 2449-2452. doi: 10.3969/j.issn.1001-5256.2019.11.012
[12]	Gao Yi, Liang ZhiJun, Fu Jian. Influence of interleukin-35 on peripheral CD8+ T cell function in patients with acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(9): 2011-2016. doi: 10.3969/j.issn.1001-5256.2019.09.025
[13]	Guo Shan, Yang XueFeng. Influence of different types of cell senescence on the development and progression of liver fibrosis[J]. Journal of Clinical Hepatology, 2018, 34(3): 627-630. doi: 10.3969/j.issn.1001-5256.2018.03.042
[14]	Li Yu, Zhang Hong, Li Zhu, Liu QingE, Wang Lu, Zhang Dan, Cao NingJia, Su Li. Influence of the Notch signaling pathway on CD8⁺T lymphocyte function in patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2018, 34(2): 287-291. doi: 10.3969/j.issn.1001-5256.2018.02.014
[15]	Wu Dan, Li ZhiWei. Accurate clinical examination guarantees the whole management process of hepatitis C patients in the era of direct-acting antiviral agents[J]. Journal of Clinical Hepatology, 2017, 33(6): 1058-1062. doi: 10.3969/j.issn.1001-5256.2017.06.008
[16]	Ceng QingLei, Yu ZuJiang. Whether antiviral therapy can reduce the incidence of hepatocellular carcinoma in patients with chronic HCV infection[J]. Journal of Clinical Hepatology, 2017, 33(6): 1075-1078. doi: 10.3969/j.issn.1001-5256.2017.06.011
[17]	Zhang Jing, Wang BingYuan, Shi JunPing. Role of cell senescence in development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2016, 32(3): 442-445. doi: 10.3969/j.issn.1001-5256.2016.03.008
[18]	Ren Shan, Chen XinYue. Current research on hepatitis C virus resistance to direct-acting antiviral agents[J]. Journal of Clinical Hepatology, 2015, 31(11): 1807-1812. doi: 10.3969/j.issn.1001-5256.2015.11.010
[19]	Xian YongChao, Cheng ShuQuan, Ni Hui, Huang ChengJun. Analysis of hepatic CD4~+,CD8~+,CD20~+,and CD57~+ T lymphocytes in chronic hepatitis B patients with different HBe Ag status[J]. Journal of Clinical Hepatology, 2015, 31(4): 546-550. doi: 10.3969/j.issn.1001-5256.2015.04.017
[20]	Dong Jie, Yang XiaoFei, Shen HuanJun, Zhao RongRong, Zhao YanYan, Zhang Ye, Huang ZhangXing, Lian JianQi. Regulatory effect of gamma-chain cytokines on expression of TIM-3 on CD8~+T cells in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(2): 205-208. doi: 10.3969/j.issn.1001-5256.2015.02.015

Supplements(0)

Cited By

Cited by

Periodical cited type(4)

1.	张敏，谢承均. 桥本甲状腺炎患者CD8~+T淋巴细胞、甲状腺相关激素水平与患病风险及预后的关系. 标记免疫分析与临床. 2022(01): 45-50 .
2.	黄辉，徐列明，平键，周扬. 扶正化瘀方通过改变急性肝损伤小鼠模型肝脏CD8~+T淋巴细胞表型功能预防肝纤维化的价值分析. 临床肝胆病杂志. 2022(02): 342-346 . 本站查看
3.	李瑞娟，权会琴，王晓艳，边培育，叶传涛，范超，张颖，周云. HCV感染者直接抗病毒药物治疗对miR-181a调节CD4~+T淋巴细胞衰老相关指标的影响. 空军军医大学学报. 2022(09): 995-1000 .
4.	廖宝林，李凌华，钟活麟，李虹，李永红，陈少贞，温春燕，胡凤玉，兰芸，蔡卫平. 直接抗病毒药物治疗HIV/HCV合并感染患者长期疗效及肝纤维化改变. 中华肝脏病杂志. 2021(08): 776-780 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(4) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (861) PDF downloads(71)

Establishment of a nomogram for survival rate after liver resection for primary small hepatocellular carcinoma based on SEER data and external validation

DOI: 10.3969/j.issn.1001-5256.2022.01.017